TRCT
MEDS

Tower Research Capital (TRC)’s DataMeds AI MEDS Stock Holding History

Tower Research Capital (TRC)’s Portfolio MEDS Stock Details MEDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1K Buy
+678
New +$3.33K ﹤0.01% 4718
2026
Q1 		– Sell
-288
Closed -$5.75K – 5698
2025
Q4 		$5.75K Sell
288
-42
-13% -$1.23K ﹤0.01% 4098
2025
Q3 		$14.7K Buy
+330
New +$17.4K ﹤0.01% 3583

Other funds holding MEDS

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Tower Research Capital (TRC)'s MEDS Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in DataMeds AI (MEDS) in Q2 2026: 678 shares worth $2.1K. The stake represents ﹤0.01% of the portfolio and ranks #4718 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in MEDS as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in MEDS in Q3 2025 and has held it in 3 quarters since. The position peaked at $14.7K in Q3 2025. 9 funds tracked by Wall St. Rank hold MEDS as of Q2 2026.

  • Tower Research Capital (TRC) held 678 shares of DataMeds AI worth $2.1K as of Q2 2026.
  • DataMeds AI was a new Tower Research Capital (TRC) position in Q2 2026.
  • DataMeds AI made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4718 holding.
  • Tower Research Capital (TRC) first reported a position in DataMeds AI in Q3 2025 and has held it in 3 quarters since.
  • Tower Research Capital (TRC)'s DataMeds AI position peaked at $14.7K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held DataMeds AI as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.